We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard Gas MISSION VIEJO...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure MISSION VIEJO, CA--(Marketwired - Jun 18, 2014) - Aeolus...
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference MISSION VIEJO, CA--(Marketwired - Jun 2, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company...
Aeolus Announces Second Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program MISSION VIEJO, CA--(Marketwired - May 15, 2014) - Aeolus Pharmaceuticals...
Aeolus Announces First Quarter Fiscal Year 2014 Financial Results MISSION VIEJO, CA--(Marketwired - Feb 14, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company...
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New Formulation MISSION VIEJO, CA--(Marketwired - Feb 13, 2014) - Aeolus Pharmaceuticals, Inc...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies MISSION VIEJO...
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA MISSION VIEJO, CA--(Marketwired - Jan 23, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company...
Aeolus Announces Fiscal Year 2013 Financial Results MISSION VIEJO, CA--(Marketwired - Dec 23, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds...
Aeolus Files Application for New Patent on AEOL 10150 MISSION VIEJO, CA--(Marketwired - Dec 5, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) Filing covers synthesis, formulation and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 39147 | 1.0E-6 | CS |
12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 19574 | 1.0E-6 | CS |
26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 7435 | 1.0E-6 | CS |
52 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 11676 | 1.0E-6 | CS |
156 | -0.000799 | -99.875 | 0.0008 | 0.0008 | 1.0E-6 | 22876 | 9.018E-5 | CS |
260 | -0.001099 | -99.9090909091 | 0.0011 | 0.02 | 1.0E-6 | 220090 | 0.00530163 | CS |
Symbol | Price | Vol. |
---|---|---|
SPRVSupurva Healthcare Group Inc (PK) | US$ 0.0001 (-50.00%) | 163.23M |
ASIIAccredited Solutions Inc (PK) | US$ 0.0006 (33.33%) | 152.19M |
CBGLCannabis Global Inc (PK) | US$ 0.0001 (100.00%) | 149.39M |
GRLFGreen Leaf Innovations Inc (PK) | US$ 0.0001 (0.00%) | 118.61M |
ABQQAB International Group Corporation (PK) | US$ 0.0011 (10.00%) | 103.11M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions